Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Elena G Arias-Salgado, Paula Acuña, Elena Monzón Manzano, Monica Martin Salces, Maria Isabel Rivas Pollmar, Pilar Lopez Gotor, Nora Butta, Cedric R. Hermans, Víctor Jiménez-Yuste, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 5396.

https://doi.org/10.1182/blood-2023-187360

Published: 2023

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Víctor Jiménez-Yuste, Elise Lim, Ketna Mistry, Giuliana Ventriglia, Amy D. Shapiro

Blood (2023) 142 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2023-173081

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Víctor Jiménez-Yuste, Eunice Tzeng, Elise Lim, Giuliana Ventriglia, Amy D. Shapiro, Johannes Oldenburg, Johnny Mahlangu

Blood (2023) 142 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2023-173016

Published: 2023

Journal Articles

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Nora Butta, Elena Monzón Manzano, Paula Acuña, Elena G Arias-Salgado, Maria Isabel Rivas Pollmar, Monica Martin Salces, Ana Mendoza-Martínez, Víctor Jiménez-Yuste, Waleed Ghanima, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2023-188452

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins

Blood (2023) 142 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2023-173015

Published: 2023

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Elena Monzón Manzano, Maria Teresa Álvarez-Roman, Paula Acuña, Elena G Arias-Salgado, Raquel Ramírez Martín, Maria Cristina Pascual Izquierdo, Maria Isabel Rivas Pollmar, Monica Martin Salces, Waleed Ghanima, Víctor Jiménez-Yuste, Nora Butta

Blood (2023) 142 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2023-185706

Published: 2023

Journal Articles

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Blood (2022) 140 (Supplement 1): 10965–10966.

https://doi.org/10.1182/blood-2022-167155

Published: 2022

Journal Articles

Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery

Abel Dos Santos Ortas, Jose Manuel Martin de Bustamante Gonzalez-Iglesias, Maria Isabel Perez Vaquero, Maria Teresa Alvarez Roman, María Isabel Rivas Pollmar, Mónica Martín Salces, Eduardo Garcia Perez, Mar Gutierrez, Elena G Arias-Salgado, Nora V. Butta, Paula Acuña, Elena Monzón Manzano, Cédric Hermans, Víctor Jiménez-Yuste

Blood (2022) 140 (Supplement 1): 11302–11303.

https://doi.org/10.1182/blood-2022-167315

Published: 2022

Journal Articles

Predictive Value of Platelet Sequestration Studies in Splenectomy Response

Ana Mendoza, Nora V. Butta, Elena Monzón Manzano, Paula Acuña, Elena G Arias-Salgado, María Isabel Rivas Pollmar, Mónica Martín Salces, Mar Gutierrez, Eduardo Garcia Perez, Andres Ramirez Lopez, Leticia Gómez Serrano, Jose Manuel Martin de Bustamante Gonzalez-Iglesias, Barbara Martínez de Miguel, Elena Martínez Montalbán, Elena Dobra, Cédric Hermans, Víctor Jiménez-Yuste, María Teresa Alvarez Román

Blood (2022) 140 (Supplement 1): 2649–2651.

https://doi.org/10.1182/blood-2022-156930

Published: 2022

Journal Articles

Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid

Andres Ramirez Lopez, María Teresa Alvarez Román, María Isabel Rivas Pollmar, Mónica Martín Salces, Mar Gutierrez, Eduardo Garcia Perez, Elena G Arias-Salgado, Elena Monzón Manzano, Paula Acuña, Víctor Jiménez Yuste, Nora V. Butta, Cédric Hermans

Blood (2022) 140 (Supplement 1): 2676–2677.

https://doi.org/10.1182/blood-2022-158266

Published: 2022

Journal Articles

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Amanda Wilson, Nana Kragh, Jennifer Dumont, Jerome Mshijid, Annemieke Willemze, Linda Bystricka, Chuanwu Zhang, Angela C. Weyand, Kathelijn Fischer, Victor Jimenez-Yuste

Blood (2022) 140 (Supplement 1): 5595–5596.

https://doi.org/10.1182/blood-2022-167542

Published: 2022

Journal Articles

Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor

María Isabel Rivas Pollmar, Elena G Arias-Salgado, María Teresa Alvarez Román, Elena Monzón Manzano, Paula Acuña, Mónica Martín Salces, Sara García Barcenilla, Nora V. Butta, Cédric Hermans, Víctor Jiménez-Yuste

Blood (2022) 140 (Supplement 1): 8462–8463.

https://doi.org/10.1182/blood-2022-170037

Published: 2022

Journal Articles

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

Mercedes Gasior Kabat, Elena Monzón Manzano, Paula Acuña, María Teresa Alvarez Román, Elena G Arias-Salgado, María Isabel Rivas Pollmar, Matias Facal Giuliani, Patricia Gonzalez Marugan, Sara García Barcenilla, Fernando Gomez Aguado, Concepción Ramos Castro, Cédric Hermans, Víctor Jiménez Yuste, Nora V. Butta

Blood (2022) 140 (Supplement 1): 12266–12267.

https://doi.org/10.1182/blood-2022-167776

Published: 2022

Journal Articles

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Joaquin Martinez Lopez, Javier De La Cruz, Rodrigo Gil-Manso, Celina Benavente Cuesta, Lauren Benito, jose Angel Hernandez, Maria Regina Herraez, Pilar Herrera Puente, Mi Kwon, Keina Quiroz, Andres Arroyo, Adrian Alegre, María Pilar Llamas Sillero, Javier López Jiménez, Pedro Sanchez-Godoy, Rafael F. Duarte, Jose L. Diez Martin, Víctor Jiménez-Yuste, Julio Garcia-Suarez

Blood (2022) 140 (Supplement 1): 7924–7925.

https://doi.org/10.1182/blood-2022-169545

Published: 2022

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

Journal Articles

Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay

Maria-Isabel Bravo, Aida Raventós, Alba Pérez, Elena G Arias-Salgado, María Teresa Alvarez Román, Nora V. Butta, Víctor Jiménez-Yuste, Montserrat Costa, Todd Willis

Blood (2021) 138 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2021-147184

Published: 2021

NARROW

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery

Predictive Value of Platelet Sequestration Studies in Splenectomy Response

Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only